京新药业再度向港交所递交上市申请中信证券独家保荐_老虎社区_美港股上老虎

京新药业再度向港交所递交上市申请中信证券独家保荐

观点地产网09-21 22:32

观点网讯：9月18日，京新药业向港交所主板递交上市申请，中信证券为其独家保荐人。

京新药业是一家A股上市逾20年的制药企业，此次为其二度冲刺港股。此前其于2026年2月首次递表，后因6个月有效期届满而失效。

免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohunote.com/m/news/2669610171?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-21 22:32","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2669610171","market":"other","top_or_hot":-1,"title":"京新药业再度向港交所递交上市申请 中信证券独家保荐","media":"观点地产网","content":"<html><body><div>\n<p cms-style=\"font-L\"><font cms-style=\"font-L strong-Bold\">观点网讯：</font>9月18日，<span><a href=\"https://laohu8.com/S/002020\">京新药业</a></span><span></span>向<a href=\"https://laohu8.com/S/00388\">港交所</a>主板递交上市申请，<span><a href=\"https://laohu8.com/S/600030\">中信证券</a></span><span></span>为其独家保荐人。</p><p cms-style=\"font-L\">京新药业是一家A股上市逾20年的制药企业，此次为其二度冲刺港股。此前其于2026年2月首次递表，后因6个月有效期届满而失效。</p><p cms-style=\"font-M\">免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。</p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>京新药业再度向港交所递交上市申请 中信证券独家保荐</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n京新药业再度向港交所递交上市申请 中信证券独家保荐\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p cms-style=\"font-L\"><font cms-style=\"font-L strong-Bold\">观点网讯：</font>9月18日，<span><a href=\"https://laohu8.com/S/002020\">京新药业</a></span><span></span>向<a href=\"https://laohu8.com/S/00388\">港交所</a>主板递交上市申请，<span><a href=\"https://laohu8.com/S/600030\">中信证券</a></span><span></span>为其独家保荐人。</p><p cms-style=\"font-L\">京新药业是一家A股上市逾20年的制药企业，此次为其二度冲刺港股。此前其于2026年2月首次递表，后因6个月有效期届满而失效。</p><p cms-style=\"font-M\">免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。</p>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.sina.com.cn/stock/estate/integration/2026-09-21/doc-inisrhft7489895.shtml\">观点地产网</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://finance.sina.com.cn/stock/estate/integration/2026-09-21/doc-inisrhft7489895.shtml","article_id":"2669610171","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669610171","pubTimestamp":1790001120,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"观点网讯：9月18日，京新药业向港交所主板递交上市申请，中信证券为其独家保荐人。京新药业是一家A股上市逾20年的制药企业，此次为其二度冲刺港股。此前其于2026年2月首次递表，后因6个月有效期届满而失效。免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600030":"中信证券","BK0028":"国家队","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0276":"资本市场","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK0188":"融资融券","IPOS":"Renaissance International IPO ETF","BK0183":"MSCI概念","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1516":"腾讯概念","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK1147":"投资银行业与经纪业","LU1720050803.USD":"安联全方位中国股票基金","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0239":"医药制造","BK1521":"挪威政府全球养老基金持仓","BK0196":"行业龙头","BK1564":"中资券商股","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","06030":"中信证券","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0012":"证金概念","002020":"京新药业","LU1997245177.USD":"安联神洲A股基金","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC"},"translate_title":"Jingxin Pharmaceutical has submitted another listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600030":1.5,"002020":1.5,"HEXmain":1.5,"06030":1.5,"IPOS":1.5},"content_text":"观点网讯：9月18日，京新药业向港交所主板递交上市申请，中信证券为其独家保荐人。京新药业是一家A股上市逾20年的制药企业，此次为其二度冲刺港股。此前其于2026年2月首次递表，后因6个月有效期届满而失效。免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}